LOGIN  |  REGISTER
Chimerix

Lucira Health to Announce First Quarter 2021 Financial Results

Lucira Health, Inc. (“Lucira Health” or “Lucira”) (Nasdaq: LHDX), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits, today announced that the company will report first quarter ended March 31, 2021 financial results on Thursday, May 13, 2021. Lucira’s management will host a conference call and webcast at 1:30 p.m. PT / 4:30 p.m. ET that day to discuss the financial results and provide a corporate update.

Conference Call and Webcast Details

The conference call can be accessed by dialing (833) 562-0151 for participants in the U.S. or Canada and (661) 567-1232 for international callers, using conference ID 3562914. A live and archived webcast of the event can be accessed via the Investors page of the investor section of Lucira's website.

About Lucira Health

Lucira Health is a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits. Lucira’s testing platform produces lab quality molecular testing in a single-use, consumer-friendly, palm size test kit powered by two AA batteries. Lucira designed its test kits to provide accurate, reliable and on-the-spot molecular tests results anywhere and anytime. The LUCIRA CHECK IT (OTC) and LUCIRA COVID-19 All-In-One Test Kits (RX) are designed to provide a clinically relevant COVID-19 result within 30 minutes from sample collection. For more information, visit www.lucirahealth.com.

Investor Contact
Greg Chodaczek
This email address is being protected from spambots. You need JavaScript enabled to view it.
347-620-7010

Media Contact
Kevin Knight
This email address is being protected from spambots. You need JavaScript enabled to view it.
206-451-4823


Recursion

Stock Quote

Featured Stock

ClearPoint Neuro

ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...

CLICK TO LEARN MORE

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page